Plus   Neg

Boston Scientific Issues Prelim. Q1 Revenue Estimates - Quick Facts

Boston Scientific Corp. (BSX) said business trends through the first two months of the fiscal year were in line with company expectations. Due to the impact from COVID-19, the company now expects first quarter revenue growth on a GAAP basis to be approximately flat to up slightly versus the prior year period, and an organic revenue decline of approximately two to three percent.

Boston Scientific is also taking steps to reduce costs which include optimizing appropriate variable costs, significantly reducing the salaries of its CEO, board of directors and executive committee members, and temporarily reducing work week schedules for employees.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Moderna said Tuesday that it has reached an agreement with the U.S. to initially supply 100 million doses of its experimental vaccine for COVID-19, mRNA-1273. The U.S. government has awarded up to $1.525 billion for the vaccine. Las Vegas, Nevada-based Mr. Wok Foods has recalled about 200,000 pounds of meat and poultry products for misbranding and undeclared allergens, the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS said. The recalled products may contain known allergens such as milk, wheat, soy, peanuts, or oysters. They may also contain MSG, sesame products, or sulfites. The U.S. Food and Drug Administration approved the first oral drug to treat patients two months of age and older with spinal muscular atrophy (SMA) that can be taken at home. Roche subsidiary Genentech's Evrysdi (risdiplam) is also the second FDA-approved drug to treat this rare and often fatal genetic disease affecting muscle strength and movement.
Follow RTT